{"id":748430,"date":"2023-04-18T07:03:52","date_gmt":"2023-04-18T11:03:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/"},"modified":"2023-04-18T07:03:52","modified_gmt":"2023-04-18T11:03:52","slug":"xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/","title":{"rendered":"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations<\/b><\/p>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled \u2018<i>METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS<\/i>.\u2019 The claims in this newly issued patent cover certain pharmaceutical formulations in Xeris\u2019 Gvoke\u00ae product line, methods of use of such formulations in treating hypoglycemia, and methods of manufacturing the therapeutic formulations.<\/p>\n<p>\n\u201cXeris\u2019 strategy is to patent early and often, including through a castle\/moat approach that has led to numerous filings both at the platform and product levels. The addition of this new patent further strengthens our intellectual property position in the XeriSol\u2122 platform portion of our portfolio and has claims that will cover the Gvoke formulation, which is in all our currently marketed Gvoke products,\u201d said Paul R. Edick, Xeris\u2019 Chairman and CEO.<\/p>\n<p>\nThe Xeris patent portfolio consists of 178 total patents globally, of which 33 are U.S. issued; 128 patent applications pending globally, of which 21 are pending in the U.S.; and 60 patents pertaining to its technology platform. Xeris\u2019 XeriSol patent portfolio includes patents and applications directed to this platform formulation technology, commercial and pipeline pharmaceutical product formulations, and therapeutic methods using such formulations to treat a variety of human diseases and disorders. All patents are owned by Xeris Biopharma subsidiaries.<\/p>\n<p><b>About Xeris<\/b><\/p>\n<p>\nXeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke\u00ae, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis\u00ae, a proven therapy for primary periodic paralysis; and Recorlev\u00ae for the treatment of endogenous Cushing\u2019s syndrome. Xeris has a diverse pipeline of development and partnered programs using its formulation sciences, XeriSol\u2122 and XeriJect\u2122 to support long-term product development and commercial success.<\/p>\n<p>\nXeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xerispharma.com%2F&amp;esheet=53382821&amp;newsitemid=20230418005445&amp;lan=en-US&amp;anchor=www.xerispharma.com&amp;index=1&amp;md5=bc07a10c40f8d3adff37b1562d73a057\">www.xerispharma.com<\/a>, or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fxerispharma%3Flang%3Den&amp;esheet=53382821&amp;newsitemid=20230418005445&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=b35a22171533abf065a5e33b8fa699fd\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fxeris-pharmaceuticals%2F&amp;esheet=53382821&amp;newsitemid=20230418005445&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=8a1c6b1de092fd2e52e84b5b0988c4fe\">LinkedIn<\/a> or <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fxerispharma%2F%3Futm_source%3Dig_profile_share%26igshid%3D5fgt5rqivy22&amp;esheet=53382821&amp;newsitemid=20230418005445&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=0b82f53c03238322cc475c3e2f2d78ed\">Instagram<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAny statements in this press release about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the strength of its intellectual property position in the XeriSol\u2122 platform portion of its portfolio, prospects for the issuance of patents, , the market and therapeutic potential of its products and product candidates, its ability to successfully develop and commercialize differentiated and innovative products, continued use of its formulation sciences by development and partnered programs, the potential utility of its formulation platforms, and other statements containing the words \u201cwill,\u201d \u201cwould,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris\u2019 experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris\u2019 actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include the impact of COVID-19 on its business operations and clinical activities, our financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators\u2019 ability to protect our intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional information about potential impacts of COVID-19, financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris is set forth in the &#8220;Risk Factors&#8221; section of Xeris\u2019 most recently filed Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while believed to be reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230418005445\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230418005445\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact<br \/>\n<\/b><br \/>Allison Wey<br \/>\n<br \/>Senior Vice President, Investor Relations and Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:awey@xerispharma.com\">awey@xerispharma.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Illinois United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Medical Devices Diabetes Biotechnology Health Pharmaceutical General Health Other Science Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230418005445\/en\/1766301\/3\/xeris_BIOPHARMA_TM_L_CMYK.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled \u2018METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.\u2019 The claims in this newly issued patent cover certain pharmaceutical formulations in Xeris\u2019 Gvoke\u00ae product line, methods of use of such formulations in treating hypoglycemia, and methods of manufacturing the therapeutic formulations. \u201cXeris\u2019 strategy is to patent early and often, including through a castle\/moat approach that has led to numerous filings both at the platform &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-748430","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled \u2018METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.\u2019 The claims in this newly issued patent cover certain pharmaceutical formulations in Xeris\u2019 Gvoke\u00ae product line, methods of use of such formulations in treating hypoglycemia, and methods of manufacturing the therapeutic formulations. \u201cXeris\u2019 strategy is to patent early and often, including through a castle\/moat approach that has led to numerous filings both at the platform &hellip; Continue reading &quot;Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T11:03:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations\",\"datePublished\":\"2023-04-18T11:03:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/\"},\"wordCount\":874,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/\",\"name\":\"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-04-18T11:03:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/","og_locale":"en_US","og_type":"article","og_title":"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations - Market Newsdesk","og_description":"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled \u2018METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.\u2019 The claims in this newly issued patent cover certain pharmaceutical formulations in Xeris\u2019 Gvoke\u00ae product line, methods of use of such formulations in treating hypoglycemia, and methods of manufacturing the therapeutic formulations. \u201cXeris\u2019 strategy is to patent early and often, including through a castle\/moat approach that has led to numerous filings both at the platform &hellip; Continue reading \"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-18T11:03:52+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations","datePublished":"2023-04-18T11:03:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/"},"wordCount":874,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/","name":"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-04-18T11:03:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005445r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-announces-issuance-of-u-s-patent-covering-xerisol-formulations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol\u2122 Formulations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=748430"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748430\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=748430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=748430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=748430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}